Lung Cancer Diagnostics Market 2021 Global Size, Industry Trends, Revenue, Future Scope and Outlook 2029

Lung Cancer Diagnostics Market is expected to reach US$ 3.88 Bn. at a CAGR of 7.3% during the forecast period 2029.

Lung Cancer Diagnostics Market Overview:

Lung Cancer Diagnostics Market Segmentation:

The global lung cancer diagnostics market is divided into three segments based on the type of test: imaging tests, biopsy, and biomarkers tests. The EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, and other tests are included in the Biomarkers test. Chest X-RAY, Positron Emission Tomography (PET), Computed Tomography (CT), and other imaging tests are also included. Tests like Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, and others are also included in the Biopsy section. Since it is so simple to determine the location and size of the tumor, imaging tests are the most crucial among all the tests for the diagnosis of lung cancer. One of the report’s analyzed segments, imaging tests, is expected to grow at an 8% CAGR to reach US$2.2 billion.

The global lung cancer diagnostics market is divided into various end-user segments, including independent diagnostic laboratories, cancer research institutes, and hospital-associated labs.

As per the MMR reports, in 2022, the hospital segment possessed the highest percentage of shares, xx%. Because it provides logistically sound, well-documented, retrieved, and ordered processes. Therefore, it is anticipated that the hospital market will grow quickly as a result of the rise in private hospitals, which offer a variety of amenities, prompt medical attention, and qualified physicians. Hospitals are seeing an increase in the number of patrons.

Lung cancer is subdivided into small-cell and non-small-cell varieties according to an indicator. The expression of particular genes and cells determines the variation in small cell cancers. Small cell lung cancer typically exhibits greater aggression than non-small cell lung cancer. Non-small cell lung cancer (NSCLC) was found to be the largest segment because it accounts for nearly 81% of all cases of the disease, can detect large tumor growths, and is the most prevalent form of the disease. Novel diagnostic tests are also available for NSCLC. The cause of that is that the cancer virus targets cells directly and disrupts blood flow, which leads to reduced blood supply and death. New technologies and treatments are being developed these days, but they come at a high cost.

Market Size (Value) Estimates & Forecast By Test, 2022-2029
1. Biomarkers Tests
1.1.1. EGFR Mutation Test
1.1.2. KRAS Mutation Test
1.1.3. ALK Test
1.1.4. HER2 Test
1.1.5. Others
2. Imaging Tests
2.1.1. Computed Tomography (CT) Scan
2.1.2. Positron Emission Tomography (PET) Scan
2.1.3. Chest X-RAY
2.1.4. Others
3. Biopsy
3.1.1. Needle Biopsy
3.1.2. Bronchoscopy Biopsy
3.1.3. Open Biopsy
3.1.4. Others
Market Size (Value) Estimates & Forecast By End User, 2022-2029
1. Hospital Associated Labs
2. Independent Diagnostic Laboratories
3. Cancer Research Institutes
4. Others
Market Size (Value) Estimates & Forecast By Indication, 2022-2029
1. Non Small-cell Lung Cancer
2. Small-cell Lung Cancer

To remain ‘ahead’ of your competitors, request for a sample

@ https://www.maximizemarketresearch.com/request-sample/113284 

Lung Cancer Diagnostics Market Key Players: The key players are

1. Abbott Laboratories
2. Agilent Technologies Inc.
3. AMOY Diagnostics CO. LTD.
4.BD
5. Bio SB
6. Bio-Rad Laboratories
7. Biocartis NV
8. bioMerieux SA
9. Cancer Diagnostics Inc.
10. Danaher Corporation
11. DiaSorin S.P.A.
12. Exact Science
13. FUJIFILM Corporation
14. GE Healthcare
15. Hologic Inc.
16. Myriad Genetics Inc.
17. Quidel Corporation
18. Roche Diagnostics
19. Siemens Healthineers AG
20. Vela Diagnostics
21. Hoffmann-La Roche Ltd
22. Thermo Fisher Scientific
23. AstraZeneca plc
24. Illumina Inc.

To remain ‘ahead’ of your competitors, request for a sample

@ https://www.maximizemarketresearch.com/market-report/global-lung-cancer-diagnostics-market/113284/ 

Lung Cancer Diagnostics Market Regional Analysis:

The  Lung Cancer Diagnostics market prediction research is created after a thorough examination of many geographical areas, including Asia-Pacific, Europe, North America, and the rest of the globe. North America has the greatest power over the  Lung Cancer Diagnostics market share and will continue to be a major shareholder in the global  Lung Cancer Diagnostics market.

COVID-19 Impact Analysis on  Lung Cancer Diagnostics Market: The COVID-19 impact on the  Lung Cancer Diagnostics market is also included in the report

Key Questions Answered in the  Lung Cancer Diagnostics Market Report are:

• What will be the CAGR of the  Lung Cancer Diagnostics market during the forecast period?
• Which segment emerged as the leading segment in the  Lung Cancer Diagnostics market?
• Which are the prominent players in the  Lung Cancer Diagnostics market?

About Us